Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Capital Leases (2016 - 2020)

Historic Capital Leases for Outlook Therapeutics (OTLK) over the last 6 years, with Q2 2020 value amounting to $49162.0.

  • Outlook Therapeutics' Capital Leases fell 9853.12% to $49162.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $49162.0, marking a year-over-year decrease of 9853.12%. This contributed to the annual value of $3.4 million for FY2019, which is 253.29% down from last year.
  • As of Q2 2020, Outlook Therapeutics' Capital Leases stood at $49162.0, which was down 9853.12% from $3.3 million recorded in Q1 2020.
  • Outlook Therapeutics' Capital Leases' 5-year high stood at $3.5 million during Q1 2018, with a 5-year trough of $28067.0 in Q3 2017.
  • In the last 5 years, Outlook Therapeutics' Capital Leases had a median value of $2.1 million in 2016 and averaged $1.8 million.
  • Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 1220361.63% in 2018, then plummeted by 9853.12% in 2020.
  • Outlook Therapeutics' Capital Leases (Quarter) stood at $113082.0 in 2016, then crashed by 62.43% to $42481.0 in 2017, then soared by 7903.87% to $3.4 million in 2018, then dropped by 1.64% to $3.3 million in 2019, then tumbled by 98.53% to $49162.0 in 2020.
  • Its Capital Leases was $49162.0 in Q2 2020, compared to $3.3 million in Q1 2020 and $3.3 million in Q4 2019.